CFO gives interview at Proactive Investors after ReNeuron announces first patient treated in US Phase I/II clinical trial in retinitis pigmentosa
It is hoped that ReNeuron’s treatment will “at the very least” arrest the deterioration in eyesight caused by the disease and in the best case restore sight.
CFO gives interview at Proactive Investors after £68.4 million placing
ReNeuron was one of the best performers on the AIM market after a successful placing which had the backing of star fund manager, Neil Woodford.
CFO gives interview at IG
After fund manager Neil Woodford bought a 20% stake in ReNeuron, CFO Michael Hunt discusses the opportunities for the company.